Article
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.
Lancet (London, England) - 19 May 2012
Falchook Gerald S, Long Georgina V, Kurzrock Razelle, Kim Kevin B, Arkenau Tobias H, Brown Michael P, Hamid Omid, Infante Jeffrey R, Millward Michael, Pavlick Anna C, O'Day Steven J, Blackman Samuel C, Curtis C Martin, Lebowitz Peter, Ma Bo, Ouellet Daniele, Kefford Richard F
Abstract excerpt
BACKGROUND: Dabrafenib is an inhibitor of BRAF kinase that is selective for mutant BRAF. We aimed to assess its safety and tolerability and to establish a recommended phase 2 dose in patients with incurable solid tumours, especially those with melanoma and untreated, asymptomatic brain metastases. METHODS: We undertook a phase 1 trial between May 27, 2009, and March 20, 2012, at eight study centres in Australia...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.